ClinicalTrials.gg
RecruitingNCT06920199Updated Sep 30, 2025

Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

An Early Phase 1 interventional study of Donor-derived Treg cell injection combined with interleukin 2 in cGVHD, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China — 19 open to participants now, 25 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · China.

Planned enrollment
36th of 42
18 · median 50
Started
2025
with 9 others
Phase 1
7 of 52
3 open now
Primary completion
2027-05
later than 12 of 24 live
Registered
35th of 52
by date
Lead sponsor
3 of 52
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, this one is the 36th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 12 of the 24 other live ones, and was the 35th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

19 of the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell injection combined with recombinant human interleukin-2 in treating subjects with refractory cGVHD,and to preliminarily observe the efficacy of the study drugs in subjects with refractory cGVHD.

Read the detailed description

This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell injection combined with recombinant human interleukin-2 in treating subjects with refractory cGVHD,and to preliminarily observe the efficacy of the study drugs in subjects with refractory cGVHD.In this study, rapid titration of the first dose group and a "3+3" rule design were used for dose escalation to minimize patient exposure to ineffective doses while minimizing the occurrence of risk.Three dose groups were set up: 1×10\^6 Treg cells /kg dose group, 5.0×10\^6 Treg cells /kg dose group and 10×10\^6Treg cells /kg dose group.One infusion per dose group.

03

Conditions studied

  • cGVHD

Keywords

  • Steroid dependence
  • Refractory cGVHD
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18-70 years old, male or female;
  • The subjects had received , including cord blood transplantation;
  • TSubjects with moderate/severe cGVHD that meets the NIH diagnostic criteria (031) for dependence or resistance, meeting one of the following:

    1. There was no improvement in cGVHD in initial treatment patients treated with > 0.5mg/kg/ day or 1 mg/kg/ day every other day for at least 4 weeks;
    2. Steroid dependence: predtisone dose > 0.25 mg/kg/d or > 0.5 mg/kg/qod cGVHD relapse or progression; cGVHD recurred after two attempts to gradually reduce prednisone dose at an interval of at least 8 weeks, with prednisone dose > 0.25 mg/kg/day to be maintained.
  • Prednisone dose > 0.25 mg/kg/d for more than 4 weeks; Subjects must maintain a stable prednisone dose for 4 weeks prior to the first Treg cell infusion and not increase or discontinue other (including cyclosporine, tacrolimus, and sirolimus);
  • The score of the subjects was 0-2;
  • the expected survival of the subject is more than 3 months;
  • Liver, kidney, heart and lung function meet the following requirements (except liver and kidney dysfunction caused by cGVHD) :

    1. (calculated by Cockcroft Gault formula) ≥60 mL/min;
    2. Cardiac greater than 50%, no changes;
    3. (FEV1) in the first second of baseline lung function ≥50%, and FEV1 decline caused by cGVHD could be included;
    4. Total ≤2.0ULN; and AST≤3ULN, ALT and AST increases caused by cGVHD could be included in the group.
  • Hematopoietic function: neutrophils >1×10\^9/L, >25×10\^9/L; Supportive treatments such as platelet transfusion and other cytokines are excluded.
  • The subject or the subject's guardian can understand this experiment and has signed the .
  • Donor age 14-70 years old, male or female;
  • The ECOG score of the donor is 0-1;
  • The donor must be a hematopoietic stem cell donor who underwent allo-HSCT prior to the subject;
  • Female donors must test negative for serum or urine beta-human chorionic gonadotropin (HCG) within 3 weeks of blood collection;
  • The donor can establish the necessary venous access for collection, without the of white blood cell collection; If peripheral venous leukocyte collection is insufficient, be willing to insert a central catheter; (15) The donor agrees to donate and signs a consent form.

Exclusion criteria

Exclusion Criteria:

  • Subjects had a recurrence of primary malignant disease before receiving Treg treatment;
  • The subjects had persistent, recurrent or delayed aGVHD;
  • Continuous use of prednisone >1 mg/kg/day is required;
  • The severity of the subject's cGVHD cannot be assessed by physical examination or laboratory examination;
  • overlap syndrome;
  • The subjects had major organ (cardio-cerebrovascular, pulmonary) dysfunction not caused by cGVHD, and had previous (within 3 months) gastrointestinal active bleeding; History of uncontrolled hypertension or hypertensive crisis or hypertensive encephalopathy, history or evidence of significant cardiovascular and cerebrovascular risk, including any of the following conditions: congestive heart failure, unstable angina pectoris, arrhythmias (e.g., ventricular fibrillation, ventricular tachycardia, etc.); History of arterial thrombosis (such as stroke, ) within the last 3 months; A history of symptomatic deep vein thrombosis, pulmonary embolism, or coronary angiogenesis, defibrillation, or any clinically relevant complication or disease within the last 6 months that could pose a risk to subject safety or interfere with study evaluation, procedure, or completion;
  • The subjects are hemodialysis patients;
  • The subject or donor has an active, uncontrolled bacterial, viral, or fungal infection that requires treatment;
  • The subjects are pregnant or lactating women; Subjects who plan to become pregnant during the post-transfusion study, or within 1 year of completion or withdrawal from the study;
  • Participants who had received IL-2 therapy or drug therapy targeting IL-2 within 4 weeks prior to enrollment;
  • Received DLI treatment within 100 days before enrollment;
  • Received CAR-T or similar engineered cell therapy within 100 days prior to enrollment;
  • Had received new cGVHD therapies (including imatinib, BTK inhibitors, rituximab and other ) within 4 weeks before enrollment after transplantation;
  • Have a history of microvascular diseases such as TMA, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, etc;
  • Subjects with poor IL-2 treatment compliance;
  • Participants who participated in other CGVHD-related clinical studies within 4 weeks prior to enrollment;
  • Subjects who are known to be allergic to any component of Treg cell injection;
  • Any situation that the investigator believes would compromise the safety of the subject or interfere with the study purpose, or that the investigator considers it inappropriate to participate in the study;
  • Having a medical condition that affects the signing of written or the inability to follow study procedures; Unwilling or unable to comply with research requirements;
  • The donor was a pregnant woman.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Donor-derived Treg cell injection combined with interleukin 2

    Donor-derived Treg cell injection, injections, The first dose was 1.0× 10\^6Treg cells /kg, the second dose was 5.0×10\^6Treg cells /kg, and the third dose was 10.0×10\^6Treg cells /kg,single-dose. Interleukin 2,1 million IU/m2/d,last 13 weeks.

    Biological: Donor-derived Treg cell injection combined with interleukin 2

Interventions

  • BiologicalDonor-derived Treg cell injection combined with interleukin 2

    Subjects received Treg cell infusion at day D0, and interleukin 2 was administered subcutaneously daily from 1 week before to 12 weeks after infusion.

06

What researchers measure

Primary outcomes

  1. To evaluate the incidence of DLT in patients with refractory cGVHD treated with donor-derived Treg cell injection combined with low dose rhIL-2 injection

    To evaluate the incidence of DLT in patients with refractory cGVHD treated with donor-derived Treg cell injection combined with low dose rhIL-2 injection。 DLT is defined as any of the following conditions related to the study drug within 28 days after the subject's infusion of Treg cell injection, despite treatment: 1. Grade 4 or 5 cytokine release syndrome caused by Treg cell injection treatment; 2. Grade 3 cytokine syndrome caused by Treg cell injection treatment and no remission to grade 2 or below within 7 days; 3. Occurrence of grade 3 or higher neurotoxicity; 4. Grade 4 hematologic toxicity: caused by non-underlying disease and lasting ≥ 28 days (except for lymphopenia, neutrophil and thrombocytopenia caused by chemotherapy pretreatment); 5. Any unanticipated toxicity that necessitates discontinuation of treatment at the discretion of the investigator or collaborating unit.

    Time frame: Up to day 28

  2. Incidence of grade 3 and above adverse reactions

    Incidence of adverse events associated with the study products;Adverse events assessed according to NCI-CTCAE v5.0.

    Time frame: Through study completion, an average of 2 year

Secondary outcomes

  1. Evaluate the number of Treg cells in subjects' peripheral blood

    Evaluate the number of Treg cells in subjects' peripheral blood after donor-derived Treg cell injection administration

    Time frame: An average of 1 year

  2. Analysis of the number changes of lymphocyte subsets in peripheral blood.

    Analysis of the number changes of lymphocyte subsets in peripheral blood, Including T/B/NK cells.

    Time frame: Through study completion, an average of 2 year

  3. Score changes in the 36-Item Short Form Health Survey (SF-36)

    Adopt 36-Item Short Form Survey (SF-36)to analyze the changes in patients' scores after medication compared with baseline.

    Time frame: Through study completion, an average of 2 year

  4. Score changes in Lee Chronic Graft-versus-Host Disease Symptom Scale

    Adopt 36-Item Short Form Survey (SF-36)to analyze the changes in patients' scores after medication compared with baseline.

    Time frame: Through study completion, an average of 2 year

  5. Changes in cGVHD severity

    Changes in cGVHD severity,according to chronic graft-versus-host disease grading system.

    Time frame: Through study completion, an average of 2 year

  6. Objective Response Rate (ORR)

    To evaluate the efficacy of donor-derived Treg cells combined with low-dose IL-2 in the treatment of refractory cGVHD subjects, including 12 and 24 weeks of ORR.

    Time frame: Through study completion, an average of 2 year

  7. Patient-reported Outcomes

    Reports directly from patients on their own health, functional status, and treatment experience, excluding explanations from health care workers or anyone else. A score of ≥7 on the Lee cGVHD Symptom Scale was associated with improved quality of life.

    Time frame: Through study completion, an average of 2 year

  8. Proportion of subjects able to reduce steroid requirement to <0.25 mg/kg/ day.

    Proportion of subjects able to reduce steroid requirement to \<0.25 mg/kg/ day.

    Time frame: Through study completion, an average of 2 year

  9. Duration of response after administration (DOR)

    Duration of response after administration (DOR),Defined as the time between first remission and disease progression, new cGvHD systemic treatment, or all-cause death, whichever occurs first.

    Time frame: Through study completion, an average of 2 year

  10. Failure-free survival after administration (FFS)

    Failure-free survival after administration (FFS),The time from the beginning of cell reinfusion to the first disease progression, recurrence after remission, or death from any cause.

    Time frame: Through study completion, an average of 2 year

  11. Overall survival

    The time from cell retransfusion to death from any cause.

    Time frame: Through study completion, an average of 2 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 9, 2025
StartActual
Jun 14, 2025
Primary completionEst.
May 15, 2027
CompletionEst.
Sep 15, 2027
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06920199
Responsible party
Xianmin Song, MD (Professor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Apr 9, 2025
Start date
Jun 14, 2025
Primary completion
May 15, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Sep 30, 2025

Study contacts

xianmin song, Doctor
Contact
shongxm@139.com
18616705298
xianmin song, Doctor
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion